Report
David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

No Time for Indolence Ahead of AAAAI

Underlying
Blueprint Medicines

Blueprint Medicines is a therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy. The company's drug candidates are: avapritinib, which targets KIT and PDGFRa mutations; BLU-667, which targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or fusions; BLU-554, which targets FGFR4, a kinase that is aberrantly activated in a defined subset of patients with hepatocellular carcinoma, the common type of liver cancer; and BLU-782, which is for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the activin-like kinase 2 gene, ACVR1.

Provider
Wedbush
Wedbush

Since our founding in 1955, Wedbush has been a leader in the financial industry providing our clients with a wide range of services; including institutional sales, correspondent clearing services, equity research, corporate and municipal finance, equity market making, fixed income trading, prime brokerage, and wealth management. Headquartered in Los Angeles, with 100 registered offices, the firm focuses on dedicated service, client financial safety, continuity, and advanced technology.

Analysts
David Nierengarten

Jeffrey La Rosa

Matthew Barcus

Other Reports on these Companies
Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe
Other Reports from Wedbush
Other Reports from these Analysts
David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus
David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus
David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

ResearchPool Subscriptions

Get the most out of your insights

Get in touch